Published in Nagoya J Med Sci on February 01, 2015
Midostaurin: an emerging treatment for acute myeloid leukemia patients. J Blood Med (2016) 0.82
A comprehensive review of pacritinib in myelofibrosis. Future Oncol (2015) 0.76
Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. ACS Med Chem Lett (2016) 0.75
Frontline treatment of acute myeloid leukemia in adults. Crit Rev Oncol Hematol (2016) 0.75
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes. Onco Targets Ther (2016) 0.75
Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. Oncotarget (2016) 0.75
A genome-wide CRISPR screen identifies genes critical for resistance to FLT3 inhibitor AC220. Cancer Res (2017) 0.75
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74
Acute myeloid leukaemia. Lancet (2006) 7.74
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood (2001) 5.17
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia (1996) 5.06
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature (2012) 4.01
The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer (2003) 3.97
FLT3: ITDoes matter in leukemia. Leukemia (2003) 3.92
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood (2004) 3.84
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood (2004) 3.76
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood (2009) 3.40
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood (2002) 2.76
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene (2000) 2.73
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood (2011) 2.66
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol (2010) 2.58
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood (2001) 2.53
FLT3 as a therapeutic target in AML: still challenging after all these years. Blood (2010) 2.25
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood (2011) 2.14
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol (2001) 1.94
Retracted A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer (1989) 1.93
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell (2002) 1.91
Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood (2002) 1.68
Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene (2002) 1.56
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood (2013) 1.52
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol (2013) 1.46
Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene (1991) 1.44
Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia (2014) 1.40
Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia (1996) 1.38
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood (2003) 1.35
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood (2004) 1.33
Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood (1993) 1.32
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood (2013) 1.31
Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia (1996) 1.28
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood (2003) 1.26
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood (2009) 1.21
Drug resistance in mutant FLT3-positive AML. Oncogene (2010) 1.20
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res (1999) 1.19
Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J Med Chem (2002) 1.08
Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. Blood (2003) 1.05
Clinical significance of FLT3 in leukemia. Int J Hematol (2005) 1.04
A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood (2002) 0.97
FLT3 in human hematologic malignancies. Leuk Lymphoma (2002) 0.96
Flt3 mutations and leukaemia. Br J Haematol (2003) 0.96
Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene. Oncogene (1993) 0.93
In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor. Leukemia (2000) 0.92
Normal and oncogenic FLT3. Cell Mol Life Sci (2004) 0.92
Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells. Leuk Lymphoma (1999) 0.80
Expression of the FLT3 gene in human leukemia-lymphoma cell lines. Leukemia (1994) 0.80
Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells. Leukemia (1996) 0.78
Effects of FLT3 ligand on human leukemia cells. II. Agonistic and antagonistic effects of other cytokines. Leukemia (1996) 0.76
Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci (2016) 0.86
Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells. Sci Rep (2015) 0.82
Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia. Cancer Sci (2015) 0.79
Rhof promotes murine marginal zone B cell development. Nagoya J Med Sci (2014) 0.78
YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma. Pharmacol Res (2017) 0.77
A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration. Cancer Immunol Res (2016) 0.76
SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway. Cancer Sci (2016) 0.76
The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib. Oncotarget (2016) 0.75
Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism. Oncotarget (2016) 0.75
Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. Oncotarget (2016) 0.75
Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes. Cancer Sci (2016) 0.75
Overview: A New Era of Cancer Genome in Myeloid Malignancies. Oncology (2015) 0.75
Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group. Support Care Cancer (2017) 0.75
A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). Am J Hematol (2017) 0.75
Real-world management of infection during chemotherapy for acute leukemia in Japan: from the results of a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group. Int J Hematol (2020) 0.75
Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia. Int J Hematol (2017) 0.75
A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. Blood (2017) 0.75
Phase 2 study of intrabone single unit cord blood transplantation for hematological malignancies. Cancer Sci (2017) 0.75
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol (2017) 0.75